Nephrology

Dual BLyS/APRIL inhibition with telitacicept cut proteinuria and maintained kidney function in adults with IgA nephropathy.

Dual BLyS/APRIL inhibition with telitacicept led to significant 24h-UPCR reductions, lower progression-risk thresholds, and stable eGFR compared with placebo.

Discover groundbreaking insights from ASN Kidney Week on the SURPASS-CVOT trial.

Acute kidney injury mortality rises in wealthier nations, highlighting urgent need for targeted prevention strategies.

Sibeprenlimab shows promising results in reducing proteinuria and improving kidney health in IgA nephropathy.

A recent study reveals that younger patients with glomerular disease face a higher lifetime risk of kidney failure despite similar progression rates.

Neuen and Gale break down groundbreaking insights on Alport syndrome and glomerular diseases, including RaDaR registry data.

Discover groundbreaking findings from the FINE-ONE trial on finerenone, offering hope for type 1 diabetes patients with CKD.

Discover groundbreaking insights on SGLT2 inhibitors and their impact on kidney health, cardiovascular outcomes, and patient care at ASN Kidney Week.

New research shows nearly all adults with hypertensive chronic kidney disease benefit from a <120 mm Hg target.

New data on daily fish oil supplementation prompts discussions on clinical recommendations.

Tegoprubart shows promise as a safer alternative to tacrolimus in kidney transplants, enhancing graft function with fewer side effects.

Jonathan Barratt, MBChB, PhD, discusses 36-week atacicept data from ASN Kidney Week 2025.

New findings reveal sparsentan significantly reduces proteinuria in FSGS patients, offering hope for improved kidney health and lower failure risk.

Findings showed anxiety, depression, and sleep disorders were highly prevalent among ESRD patients undergoing maintenance hemodialysis

Finerenone significantly reduces UACR in type 1 diabetes patients with chronic kidney disease, offering new hope for treatment.

Discover groundbreaking insights from the ORIGIN 3 study on IgA nephropathy, showcasing promising results and future treatment possibilities.

Phase 3 trial results reveal atacicept significantly reduces proteinuria in IgA nephropathy, paving the way for potential FDA approval in 2026.

ABBV-CLS-628, an anti–PAPP-A monoclonal antibody, earns Orphan Drug Designation, advancing through phase 2 testing for ADPKD.

October brings FDA approvals, new KDIGO guidance, and diagnostic breakthroughs

The FDA has approved Kygevvi (doxycitine and doxribtimine), the first therapy to improve functional outcomes and survival in thymidine kinase 2 deficiency.

Kidney Week 2025 showcases groundbreaking clinical trials and FDA approvals, marking a transformative era in nephrology and kidney disease treatment.

Meta-analysis finds peritoneal and hemodialysis offer similar survival in ESRD.

Elevated neutrophil-to-lymphocyte ratio predicts early kidney decline in IgA nephropathy.